tbuckley/cabot-search huggingface dataset:
Development of Sialic Acid-coated Nanoparticles for Targeting Cancer and Efficient Evasion of the Immune System
Authors: Young-Hwa Kim, Kyung Hyun Min, Zhantong Wang, Jihoon Kim, Orit Jacobson, Peng Huang, Guizhi Zhu, Yijing Liu, Bryant Yung, Gang Niu, Xiaoyuan Chen
Journal: Theranostics (2017)

Evading the reticuloendothelial system (RES) remains a critical challenge in the development of efficient delivery and diagnostic systems for cancer.Sialic acid (N-acetylneuraminic acid, Neu5Ac) is recognized as a "self" marker by major serum protein complement factor H and shows reduced interaction with the innate immune system via sialic acid-binding immunoglobulin-like lectin (Siglec), which is known as one of the significant regulators of phagocytic evasion.Accordingly, we prepared different surface-modified gold nanoparticles (AuNPs) and investigated the effects of sialic acid on cellular and immune responses of nanoparticles in vitro and in vivo.Sialic acid modification not only facilitates evasion of the RES by suppressing the immune response, but also enhances tumor accumulation via its active targeting ability.Therefore, sialic acid modification presents a promising strategy to advance nanotechnology towards the prospect of clinical translation.
Abstract B15: Computed tomography for quantitative imaging of live cancer cells with isotropic 3D spatial resolution
Authors: Laimonas Kelbauskas, Rishabh M. Shetty, Bin Cao, Kuo-Chen Wang, Dean Smith, Hong Wang, Shih-Hui Chao, Brian Ashcroft, Margaret Kritzer, Honor Glenn, Erik Niemela, Roger H. Johnson, John Eriksson, Deirdre R. Meldrum
Journal: Cancer Research (2017)

Abstract Quantitative 3D imaging of live single tumor cells enables direct insights into the intricacies of cellular machinery while offering new ways of assessing intercellular variability. Since its invention, X-ray computed tomography has been indispensable in the clinic for cancer diagnostic and prognostic purposes due to its quantitative manner of imaging owing to the isotropic 3D spatial resolution. Although its principles have recently begun to be implemented in the optical spectral range for single cell imaging, the applications have mainly been directed towards imaging fixed cells in absorption mode for studying an important hallmark of cancer - nuclear architecture. We present an approach that utilizes the concept of computed tomography for quantitative functional 3D imaging of live single cells. The method offers truly isotropic 3D spatial resolution and enables imaging of natural suspension cells, such as non-solid tumor or immune system cells, as opposed to cells attached to substrates, as is common to the majority of other imaging approaches. We report on technical characteristics of the method as well as experimental findings of a nuclear and mitochondrial dynamics study in human myelogenous leukemia and mouse macrophage cells as a validation. The absolute quantification capability of the method makes it a powerful tool in the field of oncology by enabling direct studies of cellular and nuclear architecture dynamics in the context of tumorigenesis and progression. Citation Format: Laimonas Kelbauskas, Rishabh M. Shetty, Bin Cao, Kuo-Chen Wang, Dean Smith, Hong Wang, Shih-Hui Chao, Brian Ashcroft, Margaret Kritzer, Honor Glenn, Erik Niemela, Roger H. Johnson, John Eriksson, Deirdre R. Meldrum. Computed tomography for quantitative imaging of live cancer cells with isotropic 3D spatial resolution. [abstract]. In: Proceedings of the AACR Special Conference on Engineering and Physical Sciences in Oncology; 2016 Jun 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2017;77(2 Suppl):Abstract nr B15.
Bullying culture in NHS starts at top, says royal college head
Authors: Tom Moberly
Journal: BMJ (2017)

A bullying culture in the NHS is being passed down “from the top,” the president of the Royal College of Surgeons has said.

Speaking at the Nuffield Trust’s Health Policy Summit last week, Clare Marx said that the health service needed to have a “zero tolerance” approach towards poor management behaviour. “I think attitudes and behaviours in healthcare come from the top,” she said. “We all hear about bullying cultures. I’m ashamed to say that I don’t know a chief executive who isn’t bullied from the top, and I think that is passed down.”

She added, “They have to be very good leaders not to actually pass on those sort of behaviours.

“So we need to stand up and say, ‘I’m not going to have this, …
A Prognostic Score for Overall Survival (OS) with Azacitidine (AZA) In Higher Risk MDS Based on 282 Patients (pts), and Validated In 175 Pts From the AZA 001 Trial
Authors: Raphael Itzykson, Sylvain Thepot, Bruno Quesnel, Francois Dreyfus, Odile Beyne-Rauzy, Pascal Turlure, Christian Recher, Caroline Dartigeas, Norbert Vey, Laurence Legros, Jacques Delaunay, Celia Salanoubat, Sorin Visanica, Aspasia Stamatoullas, Françoise Isnard, Anne Marfaing-Koka, Stephane De Botton, Youcef Chelgoum, Anne-Laure Taksin, Isabelle Plantier, Shanti Ame, Simone Boehrer, Claude Gardin, CL Beach, Lionel Ades, Pierre Fenaux
Journal: Blood (2010)
Standard Administration and Fractionated Administration of Gemtuzumab Ozogamicin for Patients with Relapsed and Refractory Acute Myeloid Leukemia
Authors: Yuichi Yahagi, Noriko Usui, Yuko Yamaguchi, Nobuaki Dobashi, Shingo Yano, Yutaka Takei, Katsuki Sugiyama, Shinobu Takahara, Yoji Ogasawara, Takeshi Saito, Kinuyo Kasama, Hiroki Yokoyama, Yutaro Kamiyama, Atsushi Katsube, Keisuke Aiba
Journal: Blood (2012)
Red Cell Antigen Genotyping Compared to Standard Serological Phenotyping in Sickle Cell Disease Patients in Canada: Potential for Reducing Alloimmunization
Authors: Khalid S Al-Habsi, Andrew W. Shih, Rebecca Barty, Grace Wang, Allahna Elahie, Mona Azzam, Reda Siddiqui, Michael Parvizian, Nancy M Heddle, Uma H. Athale, Mindy Rona Goldman, Madeleine M Verhovsek
Journal: Blood (2015)
Immune Reconstitution After Double Umbilical Cord Blood Transplantation in Adults without In Vivo T Cell Depletion of the Graft.
Authors: Aikaterini Manaka, Ioannis Baltathakis, Ifigenia Tzannou, Ioannis Kakkas, Zoe Poulopoulou, Marilena Karatza, Maria Garofalaki, Irini Bika, Irini Tziotziou, Marina Papageorgiou, Spyridoula Vassiliou, John Apostolidis, Dimitri Karakasis, Nicholas Harhalakis
Journal: Blood (2010)
Health-Related Quality of Life (HRQoL) in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): Interim Results from an Open-Label Study of AMG 531.
Authors: Michael D. Tarantino, David H. Henry, Ronald S. Go, Francois Lefrere, Alan E. Lichtin, Howard R. Terebelo, Jean-Francois Viallard, Susan D. Mathias, Robert Deeter, Kun Nie, Janet L. Nichol
Journal: Blood (2007)
Incorrect Impressions Concerning Industry-Sponsored Research
Authors: Morton Satin
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Cross-circulation for extracorporeal support and recovery of the lung
Authors: John D. O’Neill, Brandon A. Guenthart, Jinho Kim, Scott Chicotka, Dawn Queen, Kenmond Fung, Charles Marboe, Alexander Romanov, Sarah X. L. Huang, Ya-Wen Chen, Hans-Willem Snoeck, Matthew Bacchetta, Gordana Vunjak-Novakovic
Journal: Nature Biomedical Engineering (2017)
Abstract OT1-02-01: Phase II neoadjuvant trial of nanoparticle almumin-bound paclitaxel and trastuzumab in patients with node-negative, Her-2 positive breast cancer (OMC-BC04)
Authors: M Iwamoto, S Tanaka, C Koda, K Kawaguchi, R Terasawa, N Sato, H Fujioka, K Kimura, K Uchiyama
Journal: Cancer Research (2017)

Abstract Background: Neoadjuvant chemotherapy plus trastuzumab results in a 30% to 50% pathologic complete response (pCR) rate in HER-2 positive breast cancer and has been associated with improved therapeutic outcomes. Thus, the pCR rate can be useful in evaluating novel agents in this patient population. Albumin-bound (nab)-paclitaxel can reduce the toxicity of Paclitaxel while maintaining its efficacy. We reported that neoadjuvant therapy using Anthracycline based regimens (EC,AC,FEC) followed by a combination with nab-Paclitaxel and Trastuzumab was effective and safe by OMC-BC01 Study (Tanaka et al. Clin Breast Cancer 15:191-196). The pCR rate was 36% and 71% in the patients with estrogen receptor-positive and negative cancer, respectively. In addition, Tolaney et al. showed that adjuvant Paclitaxel and Trastuzumab for node-negative, HER-2 positive tumors measuring up to 3 cm in greatest dimension was associated with patients outcomes that were better than expected on the basis of historical data (Tolaney et al. N Engl J MED.2015 Jan 8:372(2):134-141). We conducted a clinical Phase II, multicenter, neoadjuvant trial of combination with nanoparticle albumin-bound Paclitaxel and Trastuzumab in patients with node-negative, Her-2 positive, estrogen receptor-negative breast cancer measuring up to 3 cm in greatest dimension. Patients and Methods: nab-Paclitaxel and Trastuzumab as neoadjuvant therapy in patients with Her-2 positive, node-negative, estrogen receptor-negative breast cancer measuring up to 3 cm in greatest dimension. Patients are treated with neoadjuvant nab-Paclitaxel (260mg/m2) and Trastuzumab q21d x 4, and undergo surgery 4-6 weeks later from completing chemotherapy. The primary endpoint, pCR is defined as no evidence of invasive tumors in the final surgical sample both in the breast and axillary lymph nodes. Secondary endpoints include objective clinical response rate, histological response rate, disease-free interval, rate of breast conserving surgery, and the safety of the treatment. Accrual: Presently, a total number of 1 patient have been included since start of the study. The expected end of accrual of 30 patients will be the last quarter 2018. Citation Format: Iwamoto M, Tanaka S, Koda C, Kawaguchi K, Terasawa R, Sato N, Fujioka H, Kimura K, Uchiyama K. Phase II neoadjuvant trial of nanoparticle almumin-bound paclitaxel and trastuzumab in patients with node-negative, Her-2 positive breast cancer (OMC-BC04) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT1-02-01.
"No evidence for interstitial lung oedema by extensive pulmonary function testing at 4,559 m". C. Dehnert, A.M. Luks, G. Schendler, E. Menold, M.M. Berger, H. Mairbaurl, V. Faoro, D.M. Bailey, C. Castell, G. Hahn, P. Vock, E.R. Swenson and P. Bartsch. Eur Respir J 2010; 35: 812-820.
Journal: European Respiratory Journal (2010)
Alemtuzumab/Low Dose Radiation Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with Sickle Cell Disease (SCD)
Authors: Santosh L. Saraf, Annie L. Oh, Dolores Mahmud, Pritesh R. Patel, Karen Sweiss, Matthew Koshy, Sally Campbell-Lee, Michel Gowhari, Johara Hassan, David Peace, John G. Quigley, Irum Khan, Robert E. Molokie, Lewis L. Hsu, Nadim Mahmud, Dennis J Levinson, Victor R. Gordeuk, Damiano Rondelli
Journal: Blood (2014)
Immunodominant Minor Histocompatibility Antigen-Specific T Lymphocytes Eradicate BCR-ABL-Induced B-ALL and CML without Causing Graft-Versus-Host Disease in Mice.
Authors: Yiguo Hu, Thomas Sproule, Cong Peng, Linghong Kong, Ami Goodrich, Derry Roopenian, Shaoguang Li
Journal: Blood (2006)
Abstract P5-16-17: Population based long term outcomes of pathologic complete response after neoadjuvant chemotherapy in stage I-III breast cancer: The British Columbia experience
Authors: J Sun, L Gondara, R Diocee, C Speers, C Lohrisch, S Chia
Journal: Cancer Research (2017)

Abstract Background: Neoadjuvant chemotherapy is a treatment option for breast cancer patients (pts) with locally advanced disease and for pts with operable breast cancer who desire breast conservation. Neoadjuvant therapy also allows for early evaluation of the effectiveness of systemic therapy. Pathologic complete response (pCR) has been shown in clinical trials to be associated with improved survival. The objective of this study was to determine if the outcomes demonstrated in clinical trials can be applied in the population based setting by comparing the outcomes of breast cancer pts who achieved pCR (no invasive disease in breast and nodes) vs. those that did not achieve a pCR. Methods: This is a retrospective cohort study of stage I-III invasive breast cancer pts treated with neoadjuvant chemotherapy from 2005 to 2010 in British Columbia. Cases were identified from the Breast Cancer Outcomes Unit database. Data was collected on demographics, tumor pathology, and type of treatment (chemotherapy, endocrine therapy, trastuzumab) and linked to standard clinical outcomes. Results: 267 pts who met inclusion criteria were identified, of whom 5% had stage I, 33% Stage II and 59% Stage III breast cancer. Median follow up was 7.4 years. Overall 74 pts (28%) demonstrated a pCR and 193 pts did not. pCR pts had better 5-yr overall survival (OS) vs. non-pCR pts: 88% vs. 73% (HR 0.43, 95% CI 0.23-0.82, p=0.01). 5-yr disease free survival (DFS) was 84% in pCR pts vs. 70% in non-pCR pts (HR 0.45, 95% CI 0.24-0.83, p=0.01). Similarly, 5-yr breast cancer specific survival (BCSS) and distant disease free survival (DDFS) were significantly better in favor of the pCR cohort: HR 0.39 (95% CI 0.18-0.82, p=0.01) and HR 0.45 (95% CI 0.24-0.83, p=0.02) respectively. pCR pts were more likely to be HER2-positive and/or ER negative. Conclusions: Our population based results showed that early stage breast cancer pts who achieved pCR after neoadjuvant chemotherapy had better outcomes on all survival parameters compared to pts who did not achieve a pCR. This finding is consistent with results from neoadjuvant clinical trials and the FDA meta-analysis. These 'real world' results demonstrate that pCR can be used as a surrogate endpoint for survival outcomes even among non-trial pts. Citation Format: Sun J, Gondara L, Diocee R, Speers C, Lohrisch C, Chia S. Population based long term outcomes of pathologic complete response after neoadjuvant chemotherapy in stage I-III breast cancer: The British Columbia experience [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-16-17.
Oral health-related quality of life among children undergoing cancer therapy.
Authors: Hai Ming Wong, Chun Hung Chu, Godfrey Chi Fung Chan
Journal: Journal of Clinical Oncology (2012)

e12006 Background: Despite much interest in oral complications in cancer patients and studies reporting their prevalence, aetiology and management, there has been little understanding of how they affect the patients and the family. The aim of this study was, therefore, to assess the impact of oral complications on life quality for children undergoing cancer therapy. Methods: Seventy 6 - 14 years old paediatric patients undergoing cancer therapy in the Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, Hong Kong participated in this study. A clinical examination of the dentition and oral soft tissues was performed using criteria suggested by the World Health Organization. Clinical examination evaluated the status of: i) dental caries (DMFT/dmft Index), ii) periodontal health (CPI Index), iii) infection, such as herpes and candidiasis, iv) thrombocytopathy in the form of oral petechiae and spontaneous gingival bleeding, v) xerostomia, and vi) mucositis (WHO Mucositis Scale). Two questionnaires were filled by the children and their parents: i) the Child Perceptions Questionnaire (CPQ), and ii) a questionnaire contained simple closed questions to collect the information of oral health habits of children and demographic data from the parents. Results: Higher CPQ scores were found in children with mucositis (p &lt; 0.001), dental caries (p &lt; 0.001), children who were born in mainland China (p &lt; 0.05), or parents of lower education or income level (p &lt; 0.05). In multiple regression analyses, mucositis and dental caries were the significant predictors (p &lt; 0.001) of the higher CPQ scores among the various parents and children characteristics collected in this survey. Conclusions: The findings of this study showed that paediatric cancer patients with mucositis and dental caries had poorer oral health-related quality of life.
Abstract P1-06-05: Breast cancer organoid cultures preserve intra-tumor heterogeneity and reveal intrinsically resistant phenotypes to standard chemotherapies
Authors: ME Sowder, KA Ludwik, L Pasic, DR Brenin, TP Stricker, IG Macara, DA Lannigan
Journal: Cancer Research (2017)

Abstract Breast cancer intra-tumor heterogeneity contributes to chemotherapy resistance and decreased patient survival, yet no reliable in vitro models exist to study this phenomenon. To address this need we developed an in vitro 3D organoid culture system using primary human breast cancer tissue. A major difficulty in the development of such models is to identify robust in vitro conditions that preserve the breast cancer phenotypes observed in situ. To address this challenge we used quantitative immunofluorescence imaging to compare the cellular phenotypes in the starting tumor tissue with those observed in the tumor organoids cultured in 3D. We utilized a clustering algorithm and utility function to quantitatively assess whether tumor organoids generated in vitro faithfully recapitulated intra- and inter-tumor heterogeneity of the tumor tissue in situ. This approach generated a normalized score that reflects tissue-organoid similarity. To test the sensitivity of our method to overall changes in tissue phenotype we focused on three distinct breast cancer subtypes distinguished by expression of estrogen receptor (ER), progesterone receptor (PR) and amplification of ERBB2/HER2 (HER2). Using our approach, we successfully recapitulated the tumor phenotypes present in ER+, ER+/HER2+ and triple negative breast cancer. We discovered that EGF preserves the TNBC phenotype, whereas AREG is required for recapitulating the phenotype of ER+ and ER+/HER2+ breast cancers. Additionally, our data demonstrate that HER1 ligands drive inter- and intra-tumor heterogeneity. To investigate how intra-tumor heterogeneity contributes to therapy responses we treated organoids with standard agents used clinically to treat each of the distinct subtypes. For all tumor subtypes we observed differential vulnerabilities between patients to drug treatments. Importantly, our analysis identified divergent cellular phenotypes that have various sensitivities to chemotherapies. Taken together, our methodology provides an unprecedented view of intra-tumor heterogeneity and allows for the investigation of chemo-resistance mechanisms. Further, this approach will provide a powerful tool, which will enhance the identification of novel therapies and facilitate personalized medicine. Citation Format: Sowder ME, Ludwik KA, Pasic L, Brenin DR, Stricker TP, Macara IG, Lannigan DA. Breast cancer organoid cultures preserve intra-tumor heterogeneity and reveal intrinsically resistant phenotypes to standard chemotherapies [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-06-05.
Abstract P5-14-01: Chemotherapy randomization of the EORTC 10041/ BIG 3-04 MINDACT (microarray in node-negative and 1 to 3 positive lymph node disease may avoid chemotherapy) trial
Authors: F Cardoso, M Piccart, E Rutgers, L Slaets, L van 't Veer, G Viale, J-Y Pierga, E Brain, S Causeret, V Golfinopoulos, T Goulioti, S Knox, E Matos, P Neijenhuis, U Nitz, R Passalacqua, IT Rubio, M Saghatchian, TJ Smilde, C Sotiriou, L Stork, C Straehle, G Thomas, A Thompson, S Vrijaldenhoven, P Vuylsteke, K Tryfonidis, J Bogaerts, S Delaloge
Journal: Cancer Research (2017)

Abstract This abstract was withdrawn by the authors.
Decreasing the Sale of Sugary Beverages
Authors: Mitchell H. Katz
Journal: JAMA Internal Medicine (2017)

Marlene B. Schwartz, PhD; Glenn E. Schneider, MPH; Yoon-Young Choi, MS; Xun Li, PhD; Jennifer Harris, PhD; Tatiana Andreyeva, PhD; Maia Hyary, MPA; Nicolette Highsmith Vernick, MPA; Lawrence J. Appel, MD, MPH
Systematic evaluation of immune regulation and modulation
Authors: David F. Stroncek, Lisa H. Butterfield, Michael A. Cannarile, Madhav V. Dhodapkar, Tim F. Greten, Jean Charles Grivel, David R. Kaufman, Heidi H. Kong, Firouzeh Korangy, Peter P. Lee, Francesco Marincola, Sergio Rutella, Janet C. Siebert, Giorgio Trinchieri, Barbara Seliger
Journal: Journal for ImmunoTherapy of Cancer (2017)

Cancer immunotherapies are showing promising clinical results in a variety of malignancies. Monitoring the immune as well as the tumor response following these therapies has led to significant advancements in the field. Moreover, the identification and assessment of both predictive and prognostic biomarkers has become a key component to advancing these therapies. Thus, it is critical to develop systematic approaches to monitor the immune response and to interpret the data obtained from these assays. In order to address these issues and make recommendations to the field, the Society for Immunotherapy of Cancer reconvened the Immune Biomarkers Task Force. As a part of this Task Force, Working Group 3 (WG3) consisting of multidisciplinary experts from industry, academia, and government focused on the systematic assessment of immune regulation and modulation. In this review, the tumor microenvironment, microbiome, bone marrow, and adoptively transferred T cells will be used as examples to discuss the type and timing of sample collection. In addition, potential types of measurements, assays, and analyses will be discussed for each sample. Specifically, these recommendations will focus on the unique collection and assay requirements for the analysis of various samples as well as the high-throughput assays to evaluate potential biomarkers.
David Oliver: Why I’m changing my mind about resuscitation
Authors: David Oliver
Journal: BMJ (2017)

I’ve written before about planning end of life care,1 pragmatism in decisions regarding “do not attempt cardiopulmonary resuscitation” (DNACPR), and possible dissonance between legal rulings and clinicians’ daily realities.2 I’ve called for more measured media reporting and said that dying people need protection from undignified, distressing medicalised intervention.13

My columns and others on DNACPR have elicited many responses,45 notably from Kate Masters,67 whose father’s action led to the Tracey judgment. Kate has been contacted by many families with similar stories.

A memorable letter described resuscitation as “the routine, institutionalised electrocution and torture …
Incidence of Elevated Expression of wt1 in Primary Myelofibrosis (pmf) and Postpv-, Postet Myelofibrosis and Its Dynamics during Ruxolitinib Treatmeny
Authors: Nadiya Siordiya, Ekaterina Lisina, Pavel Butylin, Natalia Matuhina, Konstantin Bogdanov, Anna Silutina, Elza Lomaia, Andrey Zaritskiy, Marina Konopleva
Journal: Blood (2016)